Tucatinib in combination with trastuzumab is in development for the treatment of adult patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic colorectal cancer. Colorectal cancer is a type of cancer that starts in the end portions of the bowel in the digestive system, named the colon and the rectum. Metastatic cancer is cancer that has spread to other areas of the body than where it started meaning surgery is no longer a treatment option for these patients. The protein HER2 on cells promotes growth causing cancer to grow more effectively and can make the cancer harder to treat. There are currently no NICE recommended treatments for patients with HER2+ metastatic colorectal cancer.
Tucatinib with trastuzumab for treating colorectal cancer
Tucatinib in combination with trastuzumab is in development for the treatment of adult patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic colorectal cancer.